| Quantitative Assessment of Tumor Blood Flow in Mice after Treatment with Different Doses of an Antiangiogenic Agent with Contrast-enhanced Destruction-Replenishment US. | |
| | |
MedLine Citation:
|
PMID: 21292869 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Purpose: To quantify tumor blood flow by using contrast material-enhanced destruction-replenishment ultrasonography (US) to evaluate tumor response to different doses of an agent for antiangiogenic treatment in hepatoma-bearing mice, with histologic measurements of microvascular density (MVD) as the reference standard. Materials and Methods: Experiments were approved by the regional animal care committee. Mice bearing subcutaneous H22 hepatoma were treated with different doses of thalidomide, 100 mg/kg in group B and 200 mg/kg in group C. Group A (control group) was treated with 0.5% carboxylmethylcellulose. Treatment groups and the control group included 10 mice each. Contrast-enhanced US was used to evaluate the percentage of nonenhanced area, and contrast-enhanced destruction-replenishment US was used to evaluate tumor blood flow. Tumor blood flow was compared with measurements of MVD. Comparisons were made by using one-way analysis of variance and the post hoc least significant difference test for multiple comparisons. Results: Contrast-enhanced gray-scale US showed significant increases in the percentage of nonenhanced area in group C (mean, 10.56% ± 7.25 [standard deviation]), as compared with groups A (mean, 2.40% ± 3.12; P = .004) and B (mean, 3.75% ± 5.55; P = .012). Contrast-enhanced destruction-replenishment US showed significant decreases of tumor blood flow in groups B and C, as compared with group A (P = .003 and P < .001, respectively), and the blood flow in group C was significantly lower than that of group B (P = .01). Immunohistochemical analysis revealed significant decreases of MVD in groups B and C, as compared with MVD in group A (P = .002 and P < .001, respectively); however, there was no significant difference in MVD between groups B and C (P = .21). Conclusion: Quantification of tumor blood flow by using contrast-enhanced destruction-replenishment US shows the potential to guide drug dosage during antiangiogenic therapy. © RSNA, 2011. |
| | |
Authors:
|
Jian-Hua Zhou; Long-Hui Cao; Ji-Bin Liu; Wei Zheng; Min Liu; Rong-Zhen Luo; Feng Han; An-Hua Li |
Related Documents
:
|
10175149 - Quality is a matter of mind: proposed quality improvement through the implementation of... 7079889 - Transurethral prostatectomy--studies with different intravesical pressures. 20074979 - Self-sufficiency, free trade and safety. 7713599 - The development and use of oxygen-carrying blood substitutes. 20334409 - Drop production and tip-streaming phenomenon in a microfluidic flow-focusing device via... 20577599 - Quality and safety in blood supply in 2010. 21366769 - Evaluation of a metofluthrin fan vaporizer device against phlebotomine sand flies (dipt... 16004579 - Restoration of cerebral vasoreactivity by an l-type calcium channel blocker following f... 11548069 - Is environmental cadmium a serious hazard to czech population? |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-2-3 |
Journal Detail:
|
Title: Radiology Volume: - ISSN: 1527-1315 ISO Abbreviation: - Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-2-4 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0401260 Medline TA: Radiology Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Departments of Ultrasound, Anesthesiology, and Pathology, State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, 651 Dongfeng Road East, Guangzhou 510060, People's Republic of China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fracture Risk Score and Absolute Risk of Fracture.
Next Document: Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY.